Details

Last Funding Type

Post-IPO Equity

Last Funding Money Raised

£5M

Industries

Biotechnology,Commercial

Founded date

Jan 1, 2006

Number Of Employee

101 - 250

Operating Status

Active

Stock Symbol

lse:ONC

Oncimmune (USA) LLC, founded in 2006, is an industry leader in early cancer detection. Oncimmune LLC is a wholly-owned subsidiary of Oncimmune LTD based in Nottingham, England. The company is committed to advancing early cancer detection through proprietary autoantibody assay technologies based on biological technology initially identified by John Robertson, M.D., professor of surgery at Nottingham University, England, and chief scientific officer of Oncimmune LTD. Ongoing research and development is conducted by Oncimmune under the direction of Dr. Robertson. The company’s mission is to develop early cancer detection tests to identify more than 90 percent of solid-tumor cancers, which make up 70 percent of all cancers including lung, breast, colorectal, prostate, stomach, pancreatic and ovarian. As a lab service, Oncimmune’s metro Kansas City laboratory is CLIA-certified under the Clinical Laboratory Improvements Amendment of 1988. Oncimmune LTD owns a portfolio of patents including No. 7,402,403 and No. 7,205,117.

Oncimmune has acquired 1 organizations. Their most recent acquisition was Protagen on Mar 19, 2019. They acquired Protagen for £4.10M.

Date Company Name	Industry	Acquisition Type	Price
Mar 19, 2019 Protagen	Biotechnology	acquisition	£ 4.10M	Detail